RxDoctor Payments Data

Jose Gaviria, MD

Infectious Disease · Miami, FLNPI 1942207204

Payments from drug & device makers

$8,991in general payments, 2019–2025

Across 428 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • AbbVie$2K
  • Insmed, Inc.$851
  • Merck$814
  • Johnson & Johnson$800
  • Astellas Pharma US Inc$707
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$8,52895%
  • Education$4635%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,991 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$564,640
Medicare patients
418
Services billed
33,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala107$464,324
DovatoDolutegravir Sodium/Lamivudine50$155,242
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf24$104,568
TivicayDolutegravir Sodium38$88,922
PrezcobixDarunavir/Cobicistat22$57,217
TriumeqAbacavir/Dolutegravir/Lamivudi15$55,954
DescovyEmtricitabine/Tenofov Alafenam20$44,242
JulucaDolutegravir/Rilpivirine12$41,471
Daptomycin18$6,853
Methenamine Hippurate137$5,317
PremarinEstrogens, Conjugated12$5,286
ValacyclovirValacyclovir Hcl16$855
Cefadroxil21$570
Lamivudine11$263
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$596$508,565127 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca$2,206$341,589115 claims
Janssen Products, LPSymtuza$144$104,56824 claims
Johnson & JohnsonPrezcobix$800$57,21722 claims
PfizerPremarin$33$5,28612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →